Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.58 |
| ▸ | ATR | Q13535 | 11/20 | 0.53 |
| ▸ | MTOR | P42345 | 6/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406370 | 0.91 | PIK3CA (0.56) | PIK3CAATRMTORPRKDCPIK3CB | |
| SCHEMBL1029257 | 0.90 | PIK3CA (0.56) | PIK3CAATRMTORPRKDCPIK3CB | |
| SCHEMBL13800994 | 0.88 | PIK3CA (0.74) | PIK3CAATRPIK3CBPIK3CGPIK3CD | |
| SCHEMBL1025284 | 0.86 | PIK3CA (0.52) | PIK3CAATRMTORPRKDCPIK3CB | |
| SCHEMBL13220255 | 0.85 | PIK3CA (0.79) | PIK3CAATRMTORPIK3CBPIK3CG | |
| SCHEMBL13336861 | 0.85 | PIK3CA (0.79) | PIK3CAATRMTORPRKDCPIK3CB | |
| SCHEMBL13406375 | 0.85 | PIK3CA (0.74) | PIK3CAATRMTORPIK3CBPIK3CG | |
| SCHEMBL13406364 | 0.84 | PIK3CA (0.57) | PIK3CAATRMTORPRKDCPIK3CB | |
| SCHEMBL1309608 | 0.84 | PIK3CA (0.57) | PIK3CAMTORPIK3CBPIK3CGPIK3CD | |
| SCHEMBL3608310 | 0.82 | PIK3CA (0.61) | PIK3CAATRMTORPRKDCPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| WO-2007042810-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | PIK3CA 1/4885ATR 650/4885MTOR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.